

reasons set forth below and submits that this claim should be properly grouped with the claims 10-18 of Group II. The invention of Groups I, IV, and V (claims 1-9 and 20-24) are therefore cancelled as directed to non-elected subject matter without prejudice to Applicants' right to pursue the prosecution of that Invention and claims in a further divisional application.

Applicant respectfully traverses the restriction under 35 U.S.C. § 121 to the extent that claim 19 has been restricted from the invention of Group II. Moreover, Applicants traverse on the grounds that the method of Group II claims is particularly well suited to use in conjunction with the "apparatus" - the transgenic animal, of Group III and that a search of Group II claims would necessarily cover the animal recited in the Group III claims.

Applicants respectfully submit therefore that there is unity of the inventions recited in Group II and Group III for purposes of examination. Accordingly, reconsideration and withdrawal of the restriction requirement and an early and favorable action with respect to all of the claims in the application is respectfully requested.

No fee is deemed necessary in connection with the filing of this Amendment. However, the Commissioner is authorized to apply any fee which may now be or hereafter be due for this application to Deposit Account No. 502092.


Early and favorable action is earnestly solicited.

Respectfully submitted,

Date:

12/13/04

By:



Byron V. Olsen, Reg. No. 42,960
ATTORNEY FOR APPLICANT
GTC Biotherapeutics, Inc.
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. # (508) 370-5150
Fax # (508) 370-3797